VHCP Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

VHCP Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$7.31M	Buy	1,155,104 +150,000	+15%	+$780K	7.86%	4
2016 Q3	$4.43M	Hold	1,005,104	–	–	4.36%	6
2016 Q2	$2.85M	Buy	1,005,104 +442,161	+79%	+$1.37M	2.96%	7
2016 Q1	$1.59M	Buy	+562,943	New	+$2.5M	1.38%	15
2015 Q3	–	Sell	-373,686	Closed	-$5.58M	–	19
2015 Q2	$5.58M	Sell	373,686 -1,370,670	-79%	-$15.6M	1.57%	14
2015 Q1	$15.8M	Hold	1,744,356	–	–	3.63%	10
2014 Q4	$21.2M	Hold	1,744,356	–	–	5.84%	5
2014 Q3	$17.1M	Hold	1,744,356	–	–	7.67%	6
2014 Q2	$22.2M	Hold	1,744,356	–	–	11.89%	3
2014 Q1	$18.5M	Sell	1,744,356 -10,000	-0.6%	-$107K	9.59%	3
2013 Q4	$13.3M	Sell	1,754,356 -426,300	-20%	-$2.7M	7.18%	5
2013 Q3	$15.9M	Buy	2,180,656 +1,167,214	+115%	+$5.92M	8.77%	5
2013 Q2	$1.57M	Buy	+1,013,442	New	+$1.75M	1.17%	15

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VHCP Management's BCRX Position: Q4 2016 in Review

VHCP Management increased its BioCryst Pharmaceuticals (BCRX) stake by 15% in Q4 2016, buying an estimated $780K and bringing the position to 1,155,104 shares worth $7.31M. The position accounts for 7.86% of the portfolio, ranked #4.

VHCP Management first reported a position in BCRX in Q2 2013 and has held it in 13 quarters since. The position peaked at $22.2M in Q2 2014. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

VHCP Management held 1,155,104 shares of BioCryst Pharmaceuticals worth $7.31M as of Q4 2016.
VHCP Management bought 150,000 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $780K.
BioCryst Pharmaceuticals made up 7.86% of VHCP Management's portfolio in Q4 2016, its #4 holding.
VHCP Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
VHCP Management's BioCryst Pharmaceuticals position peaked at $22.2M in Q2 2014.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.